Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: June 27, 2024
Context: The filing discloses amendments to warrant agreements with an institutional investor regarding the purchase of ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and securities amendments rather than financial performance.
Material Changes
On June 26, 2024, the Company amended two warrant agreements with an institutional investor:
- 2023 Warrant: Amended to adjust the "Redemption Right" and extend the termination date to October 12, 2029. This warrant covers up to 3,000,000 ordinary shares.
- 2024 Warrant: Amended to extend the termination date to October 12, 2029. This warrant covers up to 2,980,000 ordinary shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It notes that the summary of amendments is subject to the full terms of the documents attached as Exhibits 10.1 and 10.2. The report is incorporated by reference into Registration Statements on Forms S-8 and F-3.
Investor Verification Checklist
- Review Exhibit 10.1 for specific details on the adjusted "Redemption Right" for the 2023 Warrant.
- Confirm the total potential dilution from the combined 5,980,000 shares covered by the amended warrants.
- Verify the impact of the extended termination date (October 12, 2029) on future capital structure.
- Check subsequent filings for any financial updates, as this 6-K contains no financial data.